Hemgenix® (etranacogene dezaparvovec-drlb)
for Hemophilia

Hemgenix (etranacogene dezaparvovec-drlb) is a one-time gene therapy for adults with hemophilia B. It delivers a functional factor IX gene to liver cells via a viral vector, increasing factor IX production to improve blood clotting. Hemgenix reduces bleeding rates and may eliminate the need for prophylactic therapy by maintaining elevated factor IX levels for years after a single infusion.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Hemophilia